No consensus has been reached on the association between the b2-adrenergic receptor polymorphisms A46G and C79G and essential hypertension risk. We performed a meta-analysis to confirm the possible association. After reviewing 303 reports in PubMed and 359 reports in Embase, we included in our meta-analysis 18 articles (20 studies) that met our inclusion criteria. The fixed-effects model and the random-effects model were applied for dichotomous outcomes to combine the results of the individual studies. There was no statistical association between A46G and hypertension risk in all subjects, Asians or Caucasians. However, an association was observed in the dominant genetic model (AA vs. (AG+GG)) (P¼0.04, odds ratio (OR)¼1.38, 95% confidence interval (CI) 1.01-1.87, P heterogeneity ¼0.98, fixed-effects model) in the subgroup of mixed Africans. No overall statistical association could be found between C79G and hypertension risk or any ethnic subgroup. In the research conducted on severe hypertension (systolic blood pressure X160 mm Hg and/or diastolic blood pressure X95 mm Hg hypertensive population), significant association was found in the dominant genetic model (CC vs. (CG+GG)) (P¼0.04, OR¼1.38, 95% CI 1.02-1.86, P heterogeneity ¼0.03, random-effects model), and there was also a borderline significance between the C79 allele and severe hypertension (P¼0.05, OR¼1.26, 95% CI 1.00-1.57, P heterogeneity ¼0.04, random-effects model). No association could be found in this study between the two polymorphisms and stage 2 hypertension. More studies stratified for different ethnicities and different stages of hypertension should be performed in the future.
INTRODUCTION
Essential hypertension is an escalating problem in modern society. It is widely considered a complex genetic trait caused by multiple susceptibility genes, the effects of which are modulated by gene-environment and gene-gene interactions. 1 As a consequence, many gene polymorphisms have been assessed as candidate determinants of the risk of hypertension.
At the molecular level, the role of the b2-adrenergic receptor, ADRB2, in hypertension has been extensively evaluated, paying particular attention to the rs1042713 (Arg16Gly, A46G) and rs1042714 (Gln27Glu, C79G) single-nucleotide polymorphisms on chromosome 5q31 to 32. 2 In vitro, compared with wild-type A46, the G46 allele displayed normal agonist binding and functional coupling to Gs, resulting in the stimulation of adenylyl cyclase activity. Similar results were found in the comparison between the C79 and G79 alleles. 3 In clinical and epidemiologic populations, some studies have indicated that the A46G polymorphism [4] [5] [6] [7] [8] [9] [10] as well as the C79G polymorphism 5, 6, 8, 10, 11 in the ADRB2 gene is associated with essential hypertension (or BP level). Other studies have been unable to replicate these findings. [12] [13] [14] [15] [16] [17] [18] [19] [20] Therefore, in spite of the large number of previous reports about the association between these two polymorphisms and hypertension, the conclusion remains unclear. To clarify the effect of A46G and C79G polymorphisms on the risk of hypertension, we conducted a meta-analysis from all eligible case-control studies published to date.
MATERIALS AND METHODS

Identification and eligibility of relevant studies
To identify all the studies that examined the association of A46G and C79G polymorphisms with hypertension, we conducted a computerized literature search of PubMed and Embase databases (before January 2010) using the following keywords and subject terms: 'adrenergic' or 'adrenoceptor' , 'polymorphism' and 'hypertension' . References of retrieved articles were also screened. If an article reported results on different ethnic sub-populations, each sub-population was treated as a separate study in our meta-analysis. Studies included in the meta-analysis had to meet all the following criteria: (i) use of an unrelated case-control design, (ii) available genotype frequency, (iii) the genotype distribution of the control population must be in HardyWeinberg equilibrium (HWE) and (iv) hypertension defined as systolic blood pressure (SBP)X140 mm Hg and/or diastolic blood pressure (DBP)X 90 mm Hg and/or treatment with antihypertensive medication; stage 2 hypertension was defined as SBPX160 mm Hg and/or DBPX100 mm Hg. [21] [22] To minimize bias in the selection of studies, two observers independently extracted the information from each study. Disagreements were resolved in consensus by discussion between the authors. If a paper did not provide relevant data, or if the data provided were not sufficient, we contacted corresponding or original authors by e-mail in order to obtain the raw data.
Data extraction
Data were collected on the genotype of A46G and C79G according to ethnicity. First author, year of publication, diagnostic standards of each study, number of cases and controls, number and frequency of genotypes, and allele frequency of both polymorphisms in cases and controls are described in Tables 1, 2a and b.
Statistical analysis
The strength of the association of A46G and C79G with hypertension was measured by an odds ratio (OR) corresponding to a 95% confidence interval (CI), which was calculated according to the method used by Woolf. 23 We examined the association between allele A of A46G and hypertension, as well as the dominant genetic model (AA vs. GG + AG), the recessive genetic model (AA + AG vs. GG) and homozygote comparison (AA vs. GG). The same method was applied to analysis of the C79G polymorphism. In our study, two models of meta-analysis were applied for dichotomous outcomes in ReviewManager 4.2 software (The Cochrane Collaboration, Oxford, UK): the fixedeffects model and the random-effects model. The fixed-effects model, using the Mantel-Haenszel method, assumed that studies were sampled from populations with the same effect size, making an adjustment to the study weights according to the in-study variance. The random-effects model, using the DerSimonian and Laird method, assumed that studies were taken from populations with varying effect sizes and calculated study weights both from in-study and between-study variances, with consideration of the extent of variation or heterogeneity. We performed a X 2 -based Q statistic test to assess the between-study heterogeneity. 24 Heterogeneity was considered significant for Po0.10 because of the low power of the statistic. The random-effects model (if Po0.10) or the fixed-effects model (if P40.10) was used to pool the results. 25 The significance of the pooled OR was determined by the Z test and a P-value of o0.05 was considered significant. For each genetic comparison, subgroup analysis according to ethnicity was considered for Asian, Caucasian and mixed African populations to estimate ethnic-specific OR. The subgroup 'mixed African' included the African-American population and the Black South African population. Subgroup analysis according to different stages of hypertension was considered for stage 2 hypertension and severe hypertension. We defined the criterion of SBPX160 mm Hg and/or DBPX95 mm Hg as 'severe hypertension' based on stage 2 hypertension, in order to expand the sample size by including the research of Kato et al. 16 When unexpected heterogeneity was detected, sensitivity analysis was performed to examine specific sensitivity of the findings. This was done by examining and recalculating the pooled association sizes and joint values of P in homogeneous subgroups, as well as after excluding studies one by one.
Publication bias was investigated by funnel plot, in which the standard error of the log (OR) of each study was plotted against its OR. Funnel plot suggested possible publication bias, which was also assessed by Egger's linear regression test. 26 In addition, we performed a t-test to determine the significance of the intercept, and a P-value of o0.05 was considered significant. HWE was tested by the X 2 -test for goodness of fit based on a web program (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). Analyses were performed using the software Stata version 7 (Stata, College Station, TX, USA) and ReviewManager 4.2. All P-values were two-sided. ADRB2 polymorphisms and hypertension Y Lou et al
RESULTS
Selection of studies
Through literature search and selection based on the inclusion criteria, 19 articles (23 studies) were identified by reviewing 303 articles in PubMed and 359 articles in Embase. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] 27, 28 Of the 19 eligible articles, the study of Gu et al. 28 was replaced by their earlier report, 10 as these two articles reported the same data. Wu et al. 5 provided data on two Chinese minorities, the Hani and Yi, residents of the remote rural area of Yunnan, China. 29 The population of the two minorities was also grouped in to Asian. 30 Tang et al., 27 Herrmann et al. 18 and Xie et al. 14 provided data on two ethnicities: Caucasian American and AfricanAmerican. The genotyping data of the normotensive controls in the population Caucasian-American in Tang et al. 27 (P HWE ¼0.048), and the African-American control subjects studied in Herrmann et al. 18 (P HWE ¼0.027) deviated from HWE. The same occurred with the data provided in Mo et al. 11 (P HWE o0.001), Ge et al. 10 (P HWE ¼0.040) and The random-effects model was used to pool the results, as the between-study heterogeneity was significant. There was no significant association between the A46 allele and hypertension in all subjects (P¼0.45, OR¼1.04, 95% CI 0.94-1.15, P heterogeneity o0.0001) (Figure 1a) . 
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Stratification analysis
Significant heterogeneity existed in five studies of Asian populations.
The random-effects model was used to pool the results. No significant association was found between ADRB2 A46G and hypertension in any statistical models (Table 3 ). The fixed-effects model was used to pool the results of the Caucasian and the mixed African populations, as the between-study heterogeneity was insignificant. In the Caucasian population, we found no significant association between ADRB2 A46G and hypertension (Table 3 ). In the mixed African population, a significant association was found between the dominant genetic model (AA vs. (AG+GG)) (P¼0.04, OR¼1.38, 95% CI 1.01-1.87, P heterogeneity ¼0.98) (Figure 1b) , while no significant association was found in other statistic models (Table 3) . No significant heterogeneity existed in three studies of stage 2 hypertension; 13 
ADRB2 C79G. Global statistical results:
Significant between-study heterogeneity existed in 16 studies when we compared the C and G alleles of C79G in relation to hypertension. The random-effects model was used to pool the results. There was no significant association between the C79 allele and hypertension in all subjects (P¼0.27, OR¼1.06, 95% CI 0.96-1.18, P heterogeneity ¼0.01) (Figure 2a) . No evidence of association was seen between C79G and hypertension in the dominant genetic model (CC vs. (CG+GG)) (P¼0.21, OR¼1.10, 95% CI 0.95-1.27, P heterogeneity ¼0.006) or in the recessive genetic model ((CC+CG) vs. GG) (P¼0.43, OR¼1.04, 95% CI 0.94-1.15, P heterogeneity ¼0.90). There was no significant association in homozygote comparison (CC vs. GG) (P¼0.40, OR¼1.05, 95% CI 0.94-1.18, P heterogeneity ¼0.93) ( Table 3) .
Stratification analysis
Significant heterogeneity existed in six studies of Asians; the randomeffects model was used for allele comparison, and no significant association was found (Table 3 ). There was also no significant association found in other genetic models conducted using Asians (Table 3 ). The fixed-effects model was used to pool the results for the Caucasian and mixed African populations, as the between-study heterogeneity was insignificant. There was no significant association with hypertension found in either population (Table 3) .
Meta-analysis in the subgroup of stage 2 hypertension could not find significant association with the C79G polymorphism in the three studies included. 10, 13, 17 No association was found between the C79 allele and stage 2 hypertension (P¼0.11, OR¼1.30, 95% CI 0.94-1.81, P heterogeneity ¼0.01, random-effects model), in the dominant genetic model (CC vs. (CG+GG)) (P¼0.09, OR¼1.47, 95% CI 0.94-2.30, P heterogeneity ¼0.02, random-effects model), in the recessive genetic model ((CC+CG) vs. GG) (P¼0.75, OR¼1.05, 95% CI 0.80-1.37, P heterogeneity ¼0.55, fixed-effects model), or in the homozygote comparison (CC vs. GG) (P¼0.57, OR¼1.10, 95% CI 0.79-1.53, P heterogeneity ¼0.74, fixed-effects model).
To uncover the potential association between C79G polymorphisms and hypertension, further research was conducted on severe hypertension (SBPX160 mm Hg and/or DBPX95 mm Hg hypertensive population); four studies were included 10, 13, 16, 17 (Table 4 ). Significant association was found in the dominant genetic model (CC vs. (CG+GG)) (P¼0.04, OR¼1.38, 95% CI 1.02-1.86, P heterogeneity ¼0.03, random-effects model) (Figure 2b) , and there was also a borderline significance between the C79 allele and hypertension (P¼0.05, OR¼1.26, 95% CI 1.00-1.57, P heterogeneity ¼0.04, random-effects model) (Figure 2c ), whereas no association was found in the recessive genetic model ((CC+CG) vs. GG) (P¼0.77, OR¼1.04, 95% CI 0.80-1.36, P heterogeneity ¼0.75, fixed-effects model) or in homozygote comparison (CC vs. GG) (P¼0.59, OR¼1.09, 95% CI 0.79-1.50, P heterogeneity ¼0.89, fixed-effects model).
Sensitivity analysis
Between-study heterogeneity existed in all the studies using Asian subjects, but not in those using Caucasians and mixed African populations. Sensitivity analysis was conducted by sequential omission of individual studies overall and of Asians. As such, the Wu et al. 5 article on the Yi Chinese minority was excluded; it appeared that the overall between-study heterogeneity no longer existed for the A46G polymorphism and no association could be found (A vs. G, P¼0.61, OR¼1.01, 95% CI 0.96-1.06, P heterogeneity ¼0.22, fixed-effects model). A similar result was found in the study of Ge et al. 10 on the Han Chinese and prevalence of the C79G, which was also excluded; it appeared there was no association found overall (C vs. G, P¼0.29, OR¼1.03, 95% CI 0.98-1.09, P heterogeneity ¼0.18, fixed-effects model). However, in the Asian population, between-study heterogeneity still existed when any single study was excluded.
Publication bias
The funnel plot was applied for comparison of A46 vs. G46 in the OR analysis of ADRB2 A46G, and Egger's test provided no evidence for funnel-plot asymmetry (t¼À0.17, P¼0.868; Figure 3a) . Similarly, no publication bias was detected for the C79G polymorphism (t¼À0.21, P¼0.838; Figure 3b ).
DISCUSSION
We performed a systematic review of the literature by means of a meta-analysis on the association between the ADRB2 A46G and C79G polymorphisms and essential hypertension, without evidence of publication bias for the outcome. To avoid reporting bias, we contacted the authors for raw data. We acquired the data, including 6495 Caucasian subjects from Gjesing et al., 20 but failed to gain information from two original studies 31, 32 of Asians, which included 1700 subjects altogether. These two papers both indicated 'negative' results of A46G and C79G polymorphisms, which were consistent with our results of meta-analysis in Asians and overall.
Sensitivity analysis revealed that when two studies on Chinese subjects 5,10 were excluded, significant overall heterogeneity did not exist. The source of heterogeneity might be attributed to two factors. The first is the genetic difference in the sub-ethnic groups of the Chinese population. In the Wu et al. study, 5 the ethnic minorities Yi and Hani were recruited for the analysis but not the Han ethnic majority. The genetic differences between these populations should not be neglected. 30 Even in Han Chinese, a recent genomewide association study suggested that certain genetic characteristics of the Han population correlated with geographical locations. 33 The genetic difference made it such that heterogeneity in the metaanalysis was inevitable. Another source of heterogeneity might be related to the quality of the studies, such as small samples and different inclusion criteria. Multicenter genome-wide association study with larger samples might help to elucidate the association between hundreds of thousands of locus variants and hypertension, which would minimize the heterogeneity of samples and would also examine the loci rarely studied by traditional single-nucleotide polymorphism genotyping technology. However, despite our best efforts, we have not found any genome-wide association study of this locus published.
In the meta-analysis of the association between the ADRB2 C79G polymorphism and hypertension, our results showed no overall association or an ethnicity-specific association. Similar results were found for the stage 2 hypertension population. Interestingly, the metaanalysis on 'severe hypertension' showed significant association between C79G and hypertension in the dominant genetic model (CC vs. (CG+GG)), as well as in the comparison of the C and G alleles. We were curious to understand why an association occurred for particular criterion in the hypertensive population, but not in the population as a whole or in the subgroups of stage 2 hypertensives. Few studies (only three articles 10, 13, 17 ) investigated the correlation between this polymorphism and stage 2 hypertension. When we defined 'severe hypertension' , the sample size expanded by more than 80%; by including the research of Kato et al., 16 significant association could be found. To avoid overestimation by possible bias of other factors, we analyzed the detailed information of these four studies. Kato et al.'s study, involving both non-diabetic and diabetic patients (Table 4) , deviated from the other three studies. To avoid potential bias because of diabetes, we excluded the diabetic subjects (294 hypertensive patients and 213 normotensive controls) and recalculated the pooled results. Significant association was stable in both models (CC vs. (CG+GG), P¼0.01, OR¼1.44, 95% CI 1.07-1.93, P heterogeneity ¼0.05, random-effects model; C vs. G, P¼0.03, OR¼1.30, 95% CI 1.03-1.66, P heterogeneity ¼0.03, random-effects model).
Cockcroft et al. 34 studied the regulation of the b 2 -adrenoceptor on vessel resistance. The results indicate that homozygotes for A46 had significantly lower basal blood flow and attenuated increases in forearm blood flow compared with the G46 homozygotes, which ADRB2 polymorphisms and hypertension Y Lou et al could be explained by the variability in vascular responsiveness to isoproterenol in the vascular bed associated with A46G polymorphism. 35 Lang et al. 36 and Johnson et al. 37 provided a schematic diagram to explain the functional difference of vascular responsiveness in Africans and Caucasians. In Africans, the degree of vasodilatation and chronotropic effects in response to isoproterenol in the forearm was markedly higher than that of Caucasians, whereas baseline blood flow was similar in the two populations. In our meta-analysis, we demonstrated association of A46G polymorphisms with essential hypertension in the subgroup of the mixed African population, but not in Caucasians. The frequency of A46 homozygotes in the mixed African population was considerably higher in hypertensives than in normotensives, whereas no association could be found in other ethnicities. This suggests that the mechanisms responsible for blunted vasodilatation mediated by b 2 -adrenoceptors in response to the administration of isoproterenol might contribute to enhanced vascular reactivity in Africans and might have a role in the pathogenesis of hypertension in Africans. Some studies have reported that in G79 subjects, locally applied isoprenaline caused larger increases in forearm blood flow 34 and dilation of hand veins 34, 35 than in C79 subjects. In other words, A46G polymorphisms and C79G polymorphisms seem to share similar mechanisms in conducting blood flow in resistance vessels. This is very likely due to the linkage disequilibrium between A46G and C79G. [38] [39] [40] Owing to linkage disequilibrium, subjects homozygous for G79 are nearly always homozygous for G46, whereas naturally occurring A46/G79 is rare. [41] [42] [43] Pojoga et al. 6 observed that AA46/ CC79 was significantly associated with higher blood pressure, which might be attributed to the enhancement of the AA46/CC79 diplotype.
In conclusion, our meta-analysis suggests significant association between the ADRB2 A46G polymorphism and hypertension in the mixed African population. The ADRB2 C79G polymorphism had significant association with an SBPX160 mm Hg and/or DBPX95 mm Hg in the hypertensive population. The role of both polymorphisms might contribute to enhanced vascular reactivity to isoproterenol in capacitance vessels. 34 More studies or large casecontrol studies, and especially studies stratified for different ethnicities and different stages of hypertension, should be performed to clarify the association between ADRB2 polymorphisms and essential hypertension. Studies on the pathophysiologic mechanisms of the possible roles of A46G and C79G in hypertension are important as well.
